Details About Generic Salt ::  Capecita

Main Medicine Class::    

(cap-eh-SITE-ah-bean)

Xeloda

Tablets for oral use

150 mg and 500 mg

Class: Pyrimidine

Antimetabolite

 Indications Treatment of resistant metastatic breast cancer.

Colorectal cancer.

 Contraindications Hypersensitivity to 5-FU.

 Route/Dosage

Breast Cancer

ADULTS: PO 2500 mg/m²/day in 2 divided doses, » 12 hr apart, for 2 wk. After a 1-wk rest period, this 3-wk cycle is repeated. Round to the nearest dose that gives a whole tablet size, rather than cutting tablets in half. Dosing adjustments for all toxicities except palmar-plantar erythrodysesthesia are needed. Once the capecitabine dose is reduced, it should not be increased. Please see manufacturer’s recommendations.

Interactions

Antacids

May increase capecitabine levels.

Cimetidine or metronidazole

May increase serum concentrations of fluorouracil and potentially increase toxicity

Fluorouracil

Drug interactions have been reported with fluorouracil, the principal active metabolite of capecitabine.

Levamisole

Risk of hepatotoxicity may be increased by concomitant administration with fluorouracil.

Leucovorin

May enhance GI toxicity of fluorouracil.

Warfarin

May alter warfarin’s effects

Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Edema. CNS: Fatigue; paresthesia; headache; dizziness; insomnia. DERMATOLOGIC: Hand-and-foot syndrome; dermatitis; nail disorder. GI: Nausea; vomiting; anorexia; diarrhea; stomatitis; abdominal pain; constipation; dyspepsia; hyperbilirubinemia. HEMATOLOGIC: Neutropenia; thrombocytopenia; anemia; lymphopenia. METABOLIC: Dehydration. MUSCULOSKELETAL: Myalgia. SPECIALSENSES: Eye irritation.

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Patients ³ 80 yr may experience a greater incidence of GI grade 3 or 4 adverse events. CAD: Use cautiously in patients with previous history of CAD. Cardiac effects: Cardiotoxicity has been associated with fluorinated pyrimidine therapy. Diarrhea: Capecitabine can induce diarrhea, sometimes severe. If grade 2, 3, or 4 diarrhea occurs, immediately interrupt administration until the diarrhea resolves or decreases in intensity to grade 1. Following grade 3 or 4 diarrhea, decrease subsequent doses of capecitabine. Fertility impairment: In mice, oral capecitabine doses of 760 mg/kg/day caused a decrease in fertility. Hand-and-foot syndrome: If grade 2 or 3 hand-and-foot syndrome occurs, interrupt administration of capecitabine until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, decrease subsequent doses of capecitabine. Hepatic function impairment: Carefully monitor patients with mild to moderate hepatic dysfunction caused by liver metastases. Hyperbilirubinemia: If grade 2 to 4 elevations in bilirubin occur, immediately interrupt administration until the hyperbilirubinemia resolves or decreases in intensity to grade 1.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Store at room temperature.
• Adminster orally and take at the end of a meal with water.
• Follow procedures for proper handling and disposal of anticancer drugs. Wear gloves and avoid skin exposure and inhalation of fumes.

 Assessment/Interventions

• Provide close monitoring for the development of diarrhea, nausea, vomiting, hand-and-foot syndrome, and stomatitis. Adjust dose based on NCIC toxicity grade and manufacturer recommendations.

OVERDOSAGE: SIGNS & SYMPTOMS   Nausea, vomiting, diarrhea, GI irritation and bleeding, bone marrow depression

 Patient/Family Education

• Inform patients of the expected adverse effects, particularly nausea, vomiting, diarrhea, and hand-and-foot syndrome.
• Instruct patients experiencing grade 2 or greater diarrhea (an increase of 4 to 6 stools/day or nocturnal stools) to stop taking capecitabine immediately. Standard antidiarrheal treatments (eg, loperamide) are recommended.
• Instruct patients experiencing grade 2 or greater nausea (food intake significantly decreased but able to eat intermittently) to stop taking capecitabine immediately.
• Instruct patients experiencing grade 2 or greater vomiting (2 to 5 episodes in a 24-hr period) to stop taking capecitabine immediately.
• Instruct patients experiencing grade 2 or greater hand-and-foot syndrome (eg, painful erythema, swelling of the hands or feet that results in discomfort affecting the patients’ activities of daily living) to stop taking capecitabine immediately.
• Instruct patients experiencing grade 2 or greater stomatitis (eg, painful erythema, edema, or ulcers of the mouth or tongue, but able to eat) to stop taking capecitabine immediately.
• Instruct patients who develop a fever of ³ 100.5°F (38°C) or other evidence of potential infection to call health care provider.

Medicscientist Drug Facts

Drugs Class ::

Indications for Drugs ::

 Indications Treatment of resistant metastatic breast cancer.

Colorectal cancer.

Drug Dose ::

 Route/Dosage

Breast Cancer

ADULTS: PO 2500 mg/m²/day in 2 divided doses, » 12 hr apart, for 2 wk. After a 1-wk rest period, this 3-wk cycle is repeated. Round to the nearest dose that gives a whole tablet size, rather than cutting tablets in half. Dosing adjustments for all toxicities except palmar-plantar erythrodysesthesia are needed. Once the capecitabine dose is reduced, it should not be increased. Please see manufacturer’s recommendations.

Contraindication ::

 Contraindications Hypersensitivity to 5-FU.

Drug Precautions ::

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Patients ³ 80 yr may experience a greater incidence of GI grade 3 or 4 adverse events. CAD: Use cautiously in patients with previous history of CAD. Cardiac effects: Cardiotoxicity has been associated with fluorinated pyrimidine therapy. Diarrhea: Capecitabine can induce diarrhea, sometimes severe. If grade 2, 3, or 4 diarrhea occurs, immediately interrupt administration until the diarrhea resolves or decreases in intensity to grade 1. Following grade 3 or 4 diarrhea, decrease subsequent doses of capecitabine. Fertility impairment: In mice, oral capecitabine doses of 760 mg/kg/day caused a decrease in fertility. Hand-and-foot syndrome: If grade 2 or 3 hand-and-foot syndrome occurs, interrupt administration of capecitabine until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, decrease subsequent doses of capecitabine. Hepatic function impairment: Carefully monitor patients with mild to moderate hepatic dysfunction caused by liver metastases. Hyperbilirubinemia: If grade 2 to 4 elevations in bilirubin occur, immediately interrupt administration until the hyperbilirubinemia resolves or decreases in intensity to grade 1.

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Edema. CNS: Fatigue; paresthesia; headache; dizziness; insomnia. DERMATOLOGIC: Hand-and-foot syndrome; dermatitis; nail disorder. GI: Nausea; vomiting; anorexia; diarrhea; stomatitis; abdominal pain; constipation; dyspepsia; hyperbilirubinemia. HEMATOLOGIC: Neutropenia; thrombocytopenia; anemia; lymphopenia. METABOLIC: Dehydration. MUSCULOSKELETAL: Myalgia. SPECIALSENSES: Eye irritation.

Drug Mode of Action ::  

Drug Interactions ::

Interactions

Antacids

May increase capecitabine levels.

Cimetidine or metronidazole

May increase serum concentrations of fluorouracil and potentially increase toxicity

Fluorouracil

Drug interactions have been reported with fluorouracil, the principal active metabolite of capecitabine.

Levamisole

Risk of hepatotoxicity may be increased by concomitant administration with fluorouracil.

Leucovorin

May enhance GI toxicity of fluorouracil.

Warfarin

May alter warfarin’s effects

Drug Assesment ::

 Assessment/Interventions

• Provide close monitoring for the development of diarrhea, nausea, vomiting, hand-and-foot syndrome, and stomatitis. Adjust dose based on NCIC toxicity grade and manufacturer recommendations.

Drug Storage/Management ::

 Administration/Storage

• Store at room temperature.
• Adminster orally and take at the end of a meal with water.
• Follow procedures for proper handling and disposal of anticancer drugs. Wear gloves and avoid skin exposure and inhalation of fumes.

Drug Notes ::

 Patient/Family Education

• Inform patients of the expected adverse effects, particularly nausea, vomiting, diarrhea, and hand-and-foot syndrome.
• Instruct patients experiencing grade 2 or greater diarrhea (an increase of 4 to 6 stools/day or nocturnal stools) to stop taking capecitabine immediately. Standard antidiarrheal treatments (eg, loperamide) are recommended.
• Instruct patients experiencing grade 2 or greater nausea (food intake significantly decreased but able to eat intermittently) to stop taking capecitabine immediately.
• Instruct patients experiencing grade 2 or greater vomiting (2 to 5 episodes in a 24-hr period) to stop taking capecitabine immediately.
• Instruct patients experiencing grade 2 or greater hand-and-foot syndrome (eg, painful erythema, swelling of the hands or feet that results in discomfort affecting the patients’ activities of daily living) to stop taking capecitabine immediately.
• Instruct patients experiencing grade 2 or greater stomatitis (eg, painful erythema, edema, or ulcers of the mouth or tongue, but able to eat) to stop taking capecitabine immediately.
• Instruct patients who develop a fever of ³ 100.5°F (38°C) or other evidence of potential infection to call health care provider.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.